NRx Prescription drugs Broadcasts the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Scientific Growth and Medical

NRx Prescription drugs Broadcasts the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Scientific Growth and Medical

  • Intensive international pharmaceutical management expertise in medical growth, operations, and medical affairs
  • Centered psychiatry apply knowledgeable in PTSD, Affective Problems and Schizophrenia
  • Confirmed monitor document in analysis as an investigator and educational grant-funded researcher
  • Visiting Scholar at Stanford College, Heart for Precision Psychological Well being and Wellness
  • Former roles at Boehringer Ingelheim and Pendulum Therapeutics

RADNOR, Pa., Dec. 5, 2022 /PRNewswire/ — NRx Prescription drugs, Inc. (Nasdaq: NRXP) (“NRx Prescription drugs”, the “Firm”), a clinical-stage central nervous system (CNS) biopharmaceutical firm, as we speak introduced the appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP as Senior Vice President, Scientific Growth and Medical Affairs.  She’s going to lead the Firm’s medical growth program and supply medical oversight throughout all indications. Dr. Carretta will report back to the Chief Government Officer and Director. 

“The NRx group is happy to have attracted a clinician with deep expertise as an investigator.  Dr. Carretta’s wealth of data will assist drive our mission to develop a first-in-class lifesaving drug for suicidal despair and PTSD.  She has invaluable expertise in each front-line care and company drug growth that may profit each sufferers and shareholders.”, stated Stephen Willard, Chief Government Officer, and Director, NRx Prescription drugs.

Dr. Carretta has in depth management expertise within the pharmaceutical trade, creating and executing methods in medical, medical scientific and regulatory affairs in addition to hiring, creating, and managing numerous medical science and medical groups globally.  She brings along with her an intensive community of key opinion leaders, well being care suppliers and researchers worldwide.

Dr. Carretta is the co-founder and managing companion at C&G Holdings, LLC and most lately labored for Boehringer Ingelheim Prescription drugs because the Government Director, Therapeutic Space Head for Scientific Growth and Medical Affairs main the CNS and Ophthalmology areas. Previous to this position, Dr. Carretta served because the Vice President, Medical and Scientific Affairs at Pendulum Therapeutics.

Prior management roles at Juul Labs included creating infrastructure and techniques which supported the corporate’s client system and her work for Novartis contributed to medical excellence for Cosentyx®, Ilaris®, Entresto® and Kisquali®, with Bayer Prescription drugs for The Betaconnect™ autoinjector used with Betaseron®, and with Teva Prescription drugs for Adasuve®.

Along with her expertise within the pharmaceutical trade, Dr. Carretta has acted as an investigator for quite a few medical trials and has labored extensively in medical apply each usually and forensic psychiatry, and in academia as a funded researcher.

Dr. Carretta holds a doctorate diploma in Nursing from Vanderbilt College and each grasp’s and bachelor’s levels in Nursing from Rutgers, The State College of New Jersey.  She is nationally board licensed as an APN-BC, AHN-BC & PMHNP. Dr. Carretta is a present visiting scholar at Stanford College, Heart for Precision Psychological Well being and Wellness.

About NRx Prescription drugs

NRx Prescription drugs is a clinical-stage biopharmaceutical firm creating therapeutics for the therapy of central nervous system issues, particularly suicidal despair and post-traumatic stress dysfunction (PTSD). The corporate’s lead program NRX-101, an oral, fixed-dose mixture of D-cycloserine and lurasidone, targets the mind’s NMDA receptor and is being investigated in a Section 3 trial underneath a Meals and Drug Administration (“FDA”) Particular Protocol Settlement and Breakthrough Remedy Designation in sufferers with bipolar despair and acute suicidal ideation, a sign for which the one authorized therapy is electroshock remedy. NRx Prescription drugs has additionally initiated a Section 2b medical trial in sufferers with Sub-Acute Suicidality, probably a considerably broader indication. The Breakthrough Remedy Designation and Particular Protocol Settlement have been awarded by the FDA primarily based on the Firm’s prior STABIL-B trial that demonstrated substantial enchancment over obtainable remedy in decreasing despair and suicidality in comparison with placebo when sufferers have been handled with NRX-101 after a single dose of ketamine.

Cautionary Be aware Concerning Ahead-Wanting Statements

This announcement of NRx Prescription drugs, Inc. consists of “forward-looking statements” throughout the which means of the “protected harbor” provisions of the U.S. Personal Securities Litigation Reform Act of 1995, which can embody, however will not be restricted to, statements relating to our monetary outlook, product growth, enterprise prospects, and market and trade developments and situations, in addition to the Firm’s methods, plans, goals, and objectives. These forward-looking statements are primarily based on present beliefs, expectations, estimates, forecasts, and projections of, in addition to assumptions made by, and data presently obtainable to, the Firm’s administration. 

The Firm assumes no obligation to revise any forward-looking assertion, whether or not on account of new info, future occasions or in any other case. Accordingly, you shouldn’t place reliance on any forward-looking assertion, and all forward-looking statements are herein certified by reference to the cautionary statements set forth above.

Molly Cogan
Sr. Director, World Communications
[email protected]

Suzanne Messere
Investor Relations
[email protected]

SOURCE NRx Prescription drugs, Inc.